DEVICE CATEGORY · MOZ
Acid, Hyaluronic, Intraarticular
FDA classification: Unknown. Device class 3.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Orthovisc Injectable Intra-Articular DevicesP030019/S028 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
SUPARTZ FXP980044/S068 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
Gelsyn-3P110005/S015 | Ibsa Institut Biochimique SA | PMA supplement | Jul 24, 2026 | FDA |
GEL-ONEP080020/S055 | Seikagaku Corp. | PMA supplement | Apr 9, 2026 | FDA |
DUROLANEP170007/S015 | Bioventus, LLC | PMA supplement | Dec 23, 2025 | FDA |
SYNOJOYNTP170016/S001 | Mesoblast | PMA supplement | Dec 23, 2025 | FDA |
SUPARTZ FX; VISCO-3P980044/S065 | Seikagaku Corp. | PMA supplement | Dec 19, 2025 | FDA |
EUFLEXXA (1% SODIUM HYALURONATE)P010029/S042 | Ferring Pharmaceuticals, Inc. | PMA supplement | Oct 16, 2025 | FDA |
SUPARTZ FXP980044/S064 | Seikagaku Corp. | PMA supplement | Aug 18, 2025 | FDA |
SUPARTZ FX; VISCO-3P980044/S063 | Seikagaku Corp. | PMA supplement | Jul 22, 2025 | FDA |
GEL-ONEP080020 | Seikagaku Corp. | PMA approval | Mar 22, 2011 | FDA |
| Ferring Pharmaceuticals, Inc. | PMA approval | Dec 3, 2004 | FDA | |
SUPARTZ FXP980044 | Seikagaku Corp. | PMA approval | Jan 24, 2001 | FDA |
Source information
Follow the FDA links to view the original records.





